UA98479C2 - Mapk/erk kinase inhibitors - Google Patents

Mapk/erk kinase inhibitors

Info

Publication number
UA98479C2
UA98479C2 UAA200907471A UAA200907471A UA98479C2 UA 98479 C2 UA98479 C2 UA 98479C2 UA A200907471 A UAA200907471 A UA A200907471A UA A200907471 A UAA200907471 A UA A200907471A UA 98479 C2 UA98479 C2 UA 98479C2
Authority
UA
Ukraine
Prior art keywords
mapk
kinase inhibitors
erk kinase
compounds
methods
Prior art date
Application number
UAA200907471A
Other languages
English (en)
Ukrainian (uk)
Inventor
Цин Дун
Сянчан Гун
Стефен В. Келдор
Тоуфике Каноуни
Николас Скора
Майкл Б. Уоллейс
Фен Чжоу
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of UA98479C2 publication Critical patent/UA98479C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

(I)Раскрыты соединения указанной формулы (I) для применения с МЕК, где переменные являются такими, как определено в данном документе.Также раскрыты фармацевтические композиции, наборы и изделия, содержащие такие соединения; способы и промежуточные соединения для получения соединений; и применение указанных соединений.
UAA200907471A 2006-12-20 2007-12-18 Mapk/erk kinase inhibitors UA98479C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87091306P 2006-12-20 2006-12-20
PCT/US2007/087913 WO2008079814A2 (en) 2006-12-20 2007-12-18 Mapk/erk kinase inhibitors

Publications (1)

Publication Number Publication Date
UA98479C2 true UA98479C2 (en) 2012-05-25

Family

ID=39462025

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200907471A UA98479C2 (en) 2006-12-20 2007-12-18 Mapk/erk kinase inhibitors

Country Status (35)

Country Link
US (4) US8293901B2 (ru)
EP (1) EP2125810B1 (ru)
JP (1) JP5513127B2 (ru)
KR (1) KR101488467B1 (ru)
CN (1) CN101679411B (ru)
AR (1) AR064640A1 (ru)
AU (1) AU2007337003B2 (ru)
BR (1) BRPI0720525B8 (ru)
CA (1) CA2673647C (ru)
CL (1) CL2007003742A1 (ru)
CO (1) CO6230984A2 (ru)
CR (1) CR10937A (ru)
DK (1) DK2125810T3 (ru)
EA (1) EA016312B1 (ru)
EC (1) ECSP099529A (ru)
ES (1) ES2430966T3 (ru)
GE (1) GEP20125511B (ru)
HR (1) HRP20130684T1 (ru)
IL (1) IL199362A (ru)
JO (1) JO2985B1 (ru)
MA (1) MA31151B1 (ru)
MX (1) MX2009006675A (ru)
MY (1) MY157871A (ru)
NO (1) NO342270B1 (ru)
NZ (1) NZ578310A (ru)
PE (1) PE20090071A1 (ru)
PL (1) PL2125810T3 (ru)
PT (1) PT2125810E (ru)
RS (1) RS52887B (ru)
SI (1) SI2125810T1 (ru)
TN (1) TN2009000249A1 (ru)
TW (1) TWI396538B (ru)
UA (1) UA98479C2 (ru)
WO (1) WO2008079814A2 (ru)
ZA (1) ZA200904682B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790649A1 (en) * 2005-11-21 2007-05-30 Sanofi-Aventis Substituted bicyclic pyrimidone derivatives
TW200800997A (en) * 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
MX2009004269A (es) 2006-10-23 2009-08-12 Takeda Pharmaceutical Inhibidores de cinasa mapk/erk.
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
WO2008115890A2 (en) 2007-03-19 2008-09-25 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
JP5453290B2 (ja) * 2007-11-12 2014-03-26 武田薬品工業株式会社 Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
US20090246198A1 (en) * 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
JP2012509267A (ja) * 2008-11-18 2012-04-19 武田薬品工業株式会社 （Ｒ）−３−（２，３−ジヒドロキシプロピル）−６−フルオロ−５−（２−フルオロ−４−ヨードフェニルアミノ）−８−メチルピリド［２，３−ｄ］ピリミジン−４，７（３Ｈ，８Ｈ）−ジオン及びその中間体を製造するためのプロセス
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
TWI505828B (zh) * 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
AR086656A1 (es) 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
UA116774C2 (uk) 2012-03-01 2018-05-10 Еррей Біофарма Інк. Інгібітори серин/треонінкінази
CN104428001A (zh) * 2012-03-30 2015-03-18 武田药品工业有限公司 Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与
EP3159342B1 (en) * 2014-06-17 2020-08-05 Cisen Pharmaceutical Co., Ltd. Pyridino[1,2-a]pyrimidone analogue used as mtor/pi3k inhibitor
WO2016009306A1 (en) * 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
KR101671404B1 (ko) * 2014-09-02 2016-11-02 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
JP2016155776A (ja) * 2015-02-24 2016-09-01 学校法人兵庫医科大学 抗腫瘍効果増強剤および抗腫瘍剤
RU2742234C1 (ru) 2017-06-23 2021-02-03 Систоун Фармасьютикалс Кумариноподобное циклическое соединение в качестве ингибитора мек и его применение
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
JP7393808B2 (ja) 2018-11-20 2023-12-07 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのナフチリジノン－アニリン化合物
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
CN117779203B (zh) * 2024-02-28 2024-05-31 西北工业大学 一种n-苄基-2-甲基-4-硝基苯胺单晶及其制备方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430148A (en) 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
BR9916904A (pt) 1999-01-13 2001-10-30 Warner Lambert Co Benzo heterociclos e seu uso como inibidores demek
GT200100016A (es) 2000-01-25 2001-10-19 Pirido[2,3,-d]pirimidin-2,7-diaminas inhibidoras de cinasas.
CN1219753C (zh) 2000-07-19 2005-09-21 沃尼尔·朗伯公司 4－碘苯氨基苯氧肟酸的氧合酯
JP4524072B2 (ja) 2000-10-23 2010-08-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規化合物
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
CN1652792A (zh) 2002-03-13 2005-08-10 阵列生物制药公司 作为mek抑制剂的n3烷基化苯并咪唑衍生物
HUE025767T2 (en) 2002-03-13 2016-05-30 Array Biopharma Inc N3-alkylated benzimidazole derivatives as MEK inhibitors
EP1636228B1 (de) * 2003-05-23 2008-10-22 AEterna Zentaris GmbH Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
WO2005002351A2 (en) 2003-07-03 2005-01-13 Sunghag Koo Ferment ginseng oil
DE602004023207D1 (de) * 2003-07-24 2009-10-29 Warner Lambert Co Benzimidazol-derivate als mek-hemmer
CN1860118A (zh) * 2003-07-29 2006-11-08 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
AU2004293019B2 (en) 2003-11-19 2010-10-28 Array Biopharma Inc. Bicyclic inhibitors of MEK and methods of use thereof
CN101006086B (zh) 2004-06-11 2010-09-29 日本烟草产业株式会社 用于治疗癌症的5-氨基-2,4,7-三氧代-3,4,7,8-四氢-2H-吡啶并[2,3-d]嘧啶衍生物和相关化合物
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
DE102004054215A1 (de) 2004-11-10 2006-05-11 Merck Patent Gmbh Pyridopyrimidinonderivate
US20070299103A1 (en) 2004-12-01 2007-12-27 Ulrich Abel [1,2,4]Triazolo[4,3-A]Pyridine Derivatives for the Treatment of Hyperproliferative Diseases
US20100056516A1 (en) 2006-07-17 2010-03-04 Williams Peter D 1-hydroxy naphthyridine compounds as anti-hiv agents
MX2009004269A (es) * 2006-10-23 2009-08-12 Takeda Pharmaceutical Inhibidores de cinasa mapk/erk.
WO2008055842A1 (en) 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Substituted 6-phenyl-pyrido [2,3-d] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
JP5453290B2 (ja) * 2007-11-12 2014-03-26 武田薬品工業株式会社 Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
US20090246198A1 (en) * 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
JP2012509267A (ja) 2008-11-18 2012-04-19 武田薬品工業株式会社 （Ｒ）−３−（２，３−ジヒドロキシプロピル）−６−フルオロ−５−（２−フルオロ−４−ヨードフェニルアミノ）−８−メチルピリド［２，３−ｄ］ピリミジン−４，７（３Ｈ，８Ｈ）−ジオン及びその中間体を製造するためのプロセス

Also Published As

Publication number Publication date
US20110065733A1 (en) 2011-03-17
CR10937A (es) 2009-11-20
AU2007337003A1 (en) 2008-07-03
JO2985B1 (ar) 2016-09-05
CN101679411A (zh) 2010-03-24
EA016312B1 (ru) 2012-04-30
US8293901B2 (en) 2012-10-23
JP5513127B2 (ja) 2014-06-04
EP2125810A2 (en) 2009-12-02
TN2009000249A1 (en) 2010-10-18
PE20090071A1 (es) 2009-04-04
BRPI0720525B8 (pt) 2021-05-25
WO2008079814A2 (en) 2008-07-03
US20120202999A1 (en) 2012-08-09
NZ578310A (en) 2012-01-12
IL199362A (en) 2013-07-31
AU2007337003A2 (en) 2009-07-30
PL2125810T3 (pl) 2013-09-30
SI2125810T1 (sl) 2013-09-30
NO342270B1 (no) 2018-04-30
AR064640A1 (es) 2009-04-15
AU2007337003B2 (en) 2013-05-02
US20080255160A1 (en) 2008-10-16
CA2673647A1 (en) 2008-07-03
CA2673647C (en) 2016-02-09
WO2008079814A3 (en) 2008-09-04
CN101679411B (zh) 2013-04-17
TWI396538B (zh) 2013-05-21
ZA200904682B (en) 2010-09-29
US8470837B2 (en) 2013-06-25
ES2430966T3 (es) 2013-11-22
CO6230984A2 (es) 2010-12-20
US20100130518A1 (en) 2010-05-27
TW200835496A (en) 2008-09-01
HRP20130684T1 (en) 2013-10-11
US8030317B2 (en) 2011-10-04
KR101488467B1 (ko) 2015-01-30
JP2010514680A (ja) 2010-05-06
MY157871A (en) 2016-07-29
NO20092692L (no) 2009-09-16
ECSP099529A (es) 2009-08-28
DK2125810T3 (da) 2013-07-29
BRPI0720525B1 (pt) 2020-03-03
BRPI0720525A2 (pt) 2014-01-07
RS52887B (en) 2014-02-28
EA200970605A1 (ru) 2009-12-30
KR20090091353A (ko) 2009-08-27
PT2125810E (pt) 2013-07-29
MA31151B1 (fr) 2010-02-01
GEP20125511B (en) 2012-05-10
MX2009006675A (es) 2009-08-12
CL2007003742A1 (es) 2008-06-13
EP2125810B1 (en) 2013-04-24

Similar Documents

Publication Publication Date Title
TN2009000249A1 (en) Mapk/erk kinase inhibitors
WO2008115890A3 (en) Mapk/erk kinase inhibitors
WO2009146034A3 (en) Mapk/erk kinase inhibitors and methods of use thereof
TN2010000131A1 (en) Polo-like kinase inhibitors
WO2008079787A8 (en) Glucokinase activators
MY150542A (en) Cmet inhibitors
WO2007117995A3 (en) Kinase inhibitors
WO2007104034A3 (en) Glucokinase activators
WO2008116107A3 (en) Piperazine derivatives as glucokinase activators
MY146989A (en) Kinase inhibitors
ATE479687T1 (de) Kinaseinhibitoren
WO2010008847A3 (en) Pi3k/m tor inhibitors
WO2008055236A3 (en) Mapk/erk kinase inhibitors
MX339476B (es) Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
WO2007143434A3 (en) Indazole and isoindole derivatives as glucokinase activating agents
MY152749A (en) Pyrazole and fused pyrazole glucokinase activators
WO2010111626A3 (en) Poly (adp-ribose) polymerase (parp) inhibitors
WO2008054956A3 (en) Kinase inhibitors
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
TN2009000151A1 (en) Mapk/erk kinase inhibitors
WO2008045834A3 (en) Kinase inhibitors
WO2009129401A8 (en) Kinase inhibitors
TN2009000130A1 (en) Kinase inhibitors
WO2008089005A3 (en) Renin inhibitors